Press Release — The Institute for
Family Overall health (IFH) and the Danish Institute Towards Torture (DIGNITY) signed a
partnership arrangement on Tuesday to further expand the achieve of Psychological Health and
Psychosocial Support (MHPSS) providers in Jordan by means of a ability-building
system for psychologists and physiotherapists, according to a press statement.اضافة اعلان
The settlement also aims to expand MHPSS to include the
personal and governmental sectors with a special concentrate on youth and analysis the
present MHPSS problem between youth via IFH’s sister business, the
Facts and Study Middle of the King Hussein Foundation.
The method is funded by Danish Arab Partnership Software
(DAPP) underneath the auspices of Denmark’s Ministry of Foreign Affairs.
Tuesday’s signing ceremony was
attended by IFH Director Dr Ibrahem Aqel, DIGNITY Deputy Director Morten Olsen,
DIGNITY Jordan Business office Director Yasar Abduh, and DAPP Senior Advisor Andreas
Thulstrup.
Partnering to
offer you psychological wellbeing aidFor the duration of the event, Aqel recommended the
strategic partnership with DIGNITY, which started in 2007, noting that this
cooperation “has contributed significantly to the implementation of many
applications that satisfy the psychological, social, and wellbeing requirements of survivors of
violence”.
“This partnership will bolster our attempts and assist for IFH’s crucial and pertinent courses, which rehabilitate and reintegrate victims of torture and violence into society.”
He recalled the first results of
the partnership with DIGNITY, which took place in 2008, when IFH launched the
very first community counselling middle to present rehabilitation expert services to survivors
of violence.
The director also highlighted the
role of DIGNITY’s coaching applications for IFH specialists in creating the
institute’s capacities and competencies nationally and regionally. He stressed
the importance of growing this partnership and cooperation involving the two
institutions in the long run.
Olsen said: “This partnership will
reinforce our efforts and support for IFH’s essential and related courses,
which rehabilitate and reintegrate victims of torture and violence into
culture. I am thrilled that our collaboration will go on in the decades to
appear.”
On behalf of DIGNITY, Olsen expressed his pleasure in the continuation of the partnership
with IFH with a emphasis on enabling entry of vulnerable youth to psychological well being
assistance.
A ‘lifeline’
for the susceptibleFor his
section, Abduh reported: “DIGNITY Jordan values enormously the continued collaboration with its
strategic partner, IFH, that has stretched for far more than a decade of one of a kind
educated psychological well being and psychosocial plans in Jordan, and appears to be forward
to renewed prosperous joint interventions within an inclusive human rights
method that will profit the vulnerable inhabitants in our place.”
Thulstrup additional: “The partnership
that we are honoring today will ensure that mental wellbeing and psychosocial
assist for victims of torture will continue less than the Human Legal rights and
Inclusion Consortium in the new section of the Danish Arab Partnership Software
(2022–2027).”
“The partnership concerning DIGNITY and
IFH embodies the highly specialised and integrative treatment expected in this
get the job done,” he famous. “Your job will be a lifeline for some of the most
vulnerable individuals in this state.”
Disclaimer: This press launch is not developed by Jordan News. We do not bear obligation for its written content. In case you have any thoughts about this push launch, please refer to the make contact with person/entity mentioned in the human body of the textual content.
Read far more Nationwide information Jordan Information 

The health and fitness insurance coverage business at big could be marshaling its forces to battle proposed cuts to Medicare Edge premiums upcoming calendar year, but a single CEO won’t look far too concerned.
Humana would really benefit from reduce costs and has in the earlier, President and CEO Bruce Broussard stated during a TD Cowen conference in Boston on Tuesday. “We discovered in decades that there is force on the charge discover, we do much improved,” he said. “I feel that 2024 will be that way.”
Humana is the next-biggest Medicare Benefit carrier with 5.1 million members, or 18{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of the sector, whilst the primary insurance provider, UnitedHealthcare, has 7.1 million policyholders and a 29{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} sector share.
The Facilities for Medicare and Medicaid Products and services issued a proposal previous month to minimize Medicare Gain premiums by 2.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in 2024, but danger adjustment and other variables will outcome in disparate outcomes between insurers. The insurance plan market has characterised the draft policy as a minimize, but CMS asserts it would outcome in an typical 1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} increase in Medicare Gain revenue for insurers. The agency plans to finalize Medicare Edge prices by April 3. In addition, CMS declared very last month it would reclaim $4.7 billion around 10 yrs from Medicare Edge carriers the company concluded ended up overpaid.
Humana would likely see an total rate reduce of 1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} less than the proposed rate recognize, TD Cowen running director for health care and senior equity analysis analyst Gary Taylor claimed at the convention.
The possibility-adjustment and oblique clinical instruction elements of CMS’ proposal are of minimal period and would not affect Medicare Advantage expansion around time, Broussard mentioned. Humana has large enrollment, favorable excellent scores and favourable associations with insurance policies brokers, which will edge the firm over opponents whether CMS cuts prices or retreats from its proposal, he stated.
The wellbeing coverage trade association AHIP and UnitedHealth Team are considerably less sanguine about the proposed rate reductions and other modern plan announcements.
“We keep on being concentrated on strengthening and enhancing Medicare Benefit and urge the administration to pull again its flawed payment design revisions for 2024,” AHIP CEO Matt Eyles explained in a news release Tuesday. UnitedHealthcare also believes CMS ought to withdraw its level recognize, a spokesperson wrote in an e mail.
Broussard echoed claims from AHIP and other individuals that vulnerable Medicare beneficiaries, such as individuals also eligible for Medicaid, may perhaps endure from reduced benefits if premiums had been trimmed. Similarly, insurers and companies engaged in benefit-based payment preparations and those people working in battling marketplaces may well be harmed, he mentioned.
Humana recommitted to Medicare Gain as its core line of organization very last month when it introduced it would halt gross sales of professional insurance guidelines, which Broussard described as a “distraction” from its govt-sponsored business enterprise. The corporation mulled providing its commercial functions to a different insurer but opted to only shut it down, he reported. “We resolved we really wanted to exit it as a final result of not becoming competitive in the marketplace and also the possibility price it experienced for us as an business,” he stated.
OBJECTIVE LONG-TERM INCENTIVE PLAN FOR SENIOR MANAGEMENT
FOR 2023 (“Objective LTIP”)
Purpose: To incentivize and retain Executives eligible for this Objective LTIP, to achieve certain corporate earnings criteria and reward Executives when such criteria are achieved, and to align the long-term interests of Executives and shareholders of USPH by compensating the Executives in shares of USPH stock that vest over time, thereby increasing the Executives’ equity interest in USPH.
Effective Date: The effective date of this Objective LTIP and the establishment of performance goals and formula for the amount payable hereunder is March 2, 2023.
Eligibility: The Executives of USPH eligible for this Objective LTIP are the Chief Executive Officer (“CEO”), the Chief Financial Officer (“CFO”), the General Counsel (“EVP”), the Chief Operating Officer West (“COO West”) and the Chief Operating Officer East (“COO East”). Terms not defined herein shall have the meaning of such term as defined in the U.S. Physical Therapy, Inc. 2003 Stock Incentive Plan (as amended) (the “2003 Plan”).
Vesting and Other Terms and Provisions: Under this Objective LTIP, Executives have an opportunity to receive Restricted Stock Awards (“RSAs”) under the U. S. Physical Therapy, Inc. 2003 Stock Incentive Plan (as amended) (the “2003 Plan”), to be granted by the Compensation Committee of the Board of Directors of USPH (as the term “Committee” is defined in Section 1.8 of the 2003 Plan) in the first quarter of 2024. The Executive must be employed by USPH or its affiliates from the Effective Date through the date of the grant to receive a RSA. All RSAs shall be granted subject to the terms of the 2003 Plan and the specific terms and conditions (including without limitation, restrictions in transfer and substantial risk of forfeiture) as determined by the Compensation Committee in its sole discretion. RSAs that are granted under this Objective LTIP will vest evenly over 16 quarters, beginning April 1, 2024 and ending January 1, 2028, subject to acceleration of vesting in the Committee’s sole discretion and based on the occurrence of certain events, as more specifically defined in the applicable Restricted Stock Agreement between the Executive and USPH and/or in the Executive’s employment agreement with USPH.
Administration: The Compensation Committee has authority to administer this Objective LTIP, grant awards and decide all questions of interpretation. The Compensation Committee shall set out the vesting and other terms of an RSA in writing. The Compensation Committee’s determinations and interpretations under this Objective LTIP
Objective Goals And Amounts That May Be Awarded: The maximum amount of RSAs that may be granted under this this Objective LTIP based on achievement of the performance goals relating to 2023 are as follows: CEO = 10,000 shares; CFO = 5,000 shares; COO East = 5,000 shares; COO West = 5,000 shares and EVP = 5,000 shares
Award Grant Date: Any RSAs granted under this program shall be granted under the 2003 Plan in the first quarter of 2024 after the Compensation Committee determines the amount, if any, of the RSAs to be granted to each Participant. In addition, RSAs shall be granted only if the participant remains employed by USPH (or its affiliates) continuously from the Effective Date through the date of the grant of the RSA. All RSAs shall be granted in writing and subject to the terms of the 2003 Plan and the specific terms and conditions (including without limitation, restrictions in transfer and substantial risk of forfeiture) as determined by the Compensation Committee in its sole discretion. RSAs that are granted under this Objective LTIP will vest evenly over 16 quarters, beginning April 1, 2024 and ending January 1, 2028, subject to acceleration of vesting based on the occurrence of certain events, as more specifically defined in the applicable Restricted Stock Agreement between the Executive and USPH and/or in the Executive’s employment agreement with USPH.
Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, and amortization, changes in revaluation of put-right liability, equity-based awards compensation expense, and other extraordinary or unusual items, and related portion for non-controlling interests.
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, March 07, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Batteries in Medical Equipment and Devices Industry” – https://www.reportlinker.com/p05817872/?utm_source=GNW Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Batteries in Medical Equipment and Devices Market to Reach $4.5 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Batteries in Medical Equipment and Devices estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$4.5 Billion by 2030, growing at aCAGR of 7.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} over the period 2022-2030. Lithium Batteries, one of the segments analyzed in the report, is projected to record 9.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Nickel-Metal Hydride Batteries segment is readjusted to a revised 4.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR for the next 8-year period.
The U.S. Market is Estimated at $666.9 Million, While China is Forecast to Grow at 13.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
The Batteries in Medical Equipment and Devices market in the U.S. is estimated at US$666.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 13.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} and 6.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR.
Select Competitors (Total 64 Featured) – Duracell Inc. – Energizer Holdings, Inc. – EnerSys – Panasonic Corporation of North America – Saft Groupe SA – Tadiran Batteries GmbH
1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Batteries in Medical Equipment and Devices – Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession Batteries in Medical Equipment And Devices: Market Outlook Rise in Demand for Home Health Care Batteries Amid COVID-19
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS Rise in Prevalence Of Chronic Diseases and Increasing Demand for Medical Devices Spurs Demand for Batteries Rise in Chronic Disease Prevalence in Millions in the US: 2009- 2019 FDA Approvals for Battery Powered Devices Regulations for Medical Device Batteries: An Insight Increasing Role of Lithium Ion Batteries in Medical Devices Concerns over Safety of Batteries Pose a Challenge Growth in Demand for Battery-powered Medical Cart Computers Increasing Adoption of Wearable Medical Device Raises Demand for More Powerful Batteries New Battery Developments in Response to Medical Device Needs Rise in Demand for Smart Batteries for Medical Devices Ultra-thin, Solid-State Batteries: A New Segment in Demand Researchers Develop Heart?s Energy to Power Life-Saving Devices Miniaturized Wireless Medical Wearables and Battery Challenges Edible Batteries for Ingestible Medical Devices: A Review Role of Advanced Lithium Batteries in Addressing Miniaturization Growth in Cordless Surgical Devices Drives the Need for Advanced Batteries
4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 2: World Historic Review for Batteries in Medical Equipment and Devices by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 3: World 16-Year Perspective for Batteries in Medical Equipment and Devices by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Lithium Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 5: World Historic Review for Lithium Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 6: World 16-Year Perspective for Lithium Batteries by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Nickel-Metal Hydride Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 8: World Historic Review for Nickel-Metal Hydride Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 9: World 16-Year Perspective for Nickel-Metal Hydride Batteries by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for Zinc-Air Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 11: World Historic Review for Zinc-Air Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 12: World 16-Year Perspective for Zinc-Air Batteries by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for Other Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 14: World Historic Review for Other Batteries by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 15: World 16-Year Perspective for Other Batteries by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Batteries in Medical Equipment and Devices Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in the United States for 2023 (E) Table 17: USA Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 18: USA Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 19: USA 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
CANADA Table 20: Canada Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 21: Canada Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 22: Canada 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
JAPAN Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Japan for 2023 (E) Table 23: Japan Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 24: Japan Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 25: Japan 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
CHINA Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in China for 2023 (E) Table 26: China Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 27: China Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 28: China 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
EUROPE Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Europe for 2023 (E) Table 29: Europe Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 30: Europe Historic Review for Batteries in Medical Equipment and Devices by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 31: Europe 16-Year Perspective for Batteries in Medical Equipment and Devices by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
Table 32: Europe Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 33: Europe Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 34: Europe 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
FRANCE Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in France for 2023 (E) Table 35: France Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 36: France Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 37: France 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
GERMANY Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Germany for 2023 (E) Table 38: Germany Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 39: Germany Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 40: Germany 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
ITALY Table 41: Italy Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 42: Italy Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 43: Italy 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
UNITED KINGDOM Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in the United Kingdom for 2023 (E) Table 44: UK Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 45: UK Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 46: UK 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
SPAIN Table 47: Spain Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 48: Spain Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 49: Spain 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
RUSSIA Table 50: Russia Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 51: Russia Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 52: Russia 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
REST OF EUROPE Table 53: Rest of Europe Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 54: Rest of Europe Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 55: Rest of Europe 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
ASIA-PACIFIC Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Asia-Pacific for 2023 (E) Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 57: Asia-Pacific Historic Review for Batteries in Medical Equipment and Devices by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 58: Asia-Pacific 16-Year Perspective for Batteries in Medical Equipment and Devices by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 60: Asia-Pacific Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 61: Asia-Pacific 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
AUSTRALIA Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Australia for 2023 (E) Table 62: Australia Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 63: Australia Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 64: Australia 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
INDIA Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in India for 2023 (E) Table 65: India Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 66: India Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 67: India 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
SOUTH KOREA Table 68: South Korea Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 69: South Korea Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 70: South Korea 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
REST OF ASIA-PACIFIC Table 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 72: Rest of Asia-Pacific Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 73: Rest of Asia-Pacific 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
LATIN AMERICA Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Latin America for 2023 (E) Table 74: Latin America Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Geographic Region – Argentina, Brazil, Mexico and Rest of Latin America Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 75: Latin America Historic Review for Batteries in Medical Equipment and Devices by Geographic Region – Argentina, Brazil, Mexico and Rest of Latin America Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 76: Latin America 16-Year Perspective for Batteries in Medical Equipment and Devices by Geographic Region – Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
Table 77: Latin America Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 78: Latin America Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 79: Latin America 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
ARGENTINA Table 80: Argentina Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 81: Argentina Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 82: Argentina 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
BRAZIL Table 83: Brazil Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 84: Brazil Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 85: Brazil 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
MEXICO Table 86: Mexico Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 87: Mexico Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 88: Mexico 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
REST OF LATIN AMERICA Table 89: Rest of Latin America Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 90: Rest of Latin America Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 91: Rest of Latin America 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
MIDDLE EAST Batteries in Medical Equipment and Devices Market Presence – Strong/Active/Niche/Trivial – Key Competitors in Middle East for 2023 (E) Table 92: Middle East Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Geographic Region – Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets – Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 93: Middle East Historic Review for Batteries in Medical Equipment and Devices by Geographic Region – Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 94: Middle East 16-Year Perspective for Batteries in Medical Equipment and Devices by Geographic Region – Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
Table 95: Middle East Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 96: Middle East Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 97: Middle East 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
IRAN Table 98: Iran Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 99: Iran Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries Markets – Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 100: Iran 16-Year Perspective for Batteries in Medical Equipment and Devices by Type – Percentage Breakdown of Value Sales for Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries for the Years 2014, 2023 & 2030
ISRAEL Table 101: Israel Recent Past, Current & Future Analysis for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal Hydride Batteries, Zinc-Air Batteries and Other Batteries – Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} CAGR
Table 102: Israel Historic Review for Batteries in Medical Equipment and Devices by Type – Lithium Batteries, Nickel-Metal
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
NEW YORK, March 7, 2023 /PRNewswire/ — According to Technavio, the size of the K-12 online education market in china is estimated to grow by USD 18.93 billion from 2021 to 2026. The market is estimated to grow at a CAGR of 15.45{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} during the forecast period. The growing customization of online education services is a key trend in the market. Vendors are extending their product portfolio and service offerings owing to high competition. They are integrating technology and education to ensure higher student engagement and make the learning environment more collaborative. Customized learning helps teachers adjust the learning pace based on the requirements of students. The schedule includes learning tasks and supplementary study materials based on the abilities of each student. This technique helps develop the learning ability and productivity of students and enhances their learning experience. For more insights on the market – Request a sample report
Technavio has announced its latest market research report titled K-12 Online Education Market in China
What’s New?
Special coverage on the Russia–Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
Global competitiveness and key competitor positions
Market presence across multiple geographical footprints – Strong/Active/Niche/Trivial – buy the report!
K-12 online education market in China – Segmentation assessment Segment overview Technavio has segmented the market based on product (online schools, language learning courses, and test preparation services) and end-user (institutional learners and individual learners).
The online schools segment will account for a significant share of the market’s growth during the forecast period. The demand for online schools in China is growing owing to their flexibility and convenience when compared to traditional schools. This, in turn, will drive the segment’s growth during the forecast period.
The increase in adoption of online test preparation courses is driving the market growth.
The rising spending on education by Chinese households and a rise in the number of private institutions are leading to an increase in the number of graduates.
Many parents enroll their children in programs to enhance their academic performance.
For instance, students must clear Gaokao, Scholastic Aptitude Test (SAT), or Graduate Record Examinations (GRE) to pursue higher education in domestic and foreign universities.
These factors will boost the growth of the K-12 online education market in China during the forecast period.
Major challenges hindering the market growth
The lack of socializing opportunities for students is challenging the market growth.
In most online programs in China, one teacher is assigned to a number of students in a virtual class.
As a result, there is a low possibility for one-to-one interaction.
This leads to a lack of socializing opportunities for students, unlike in conventional school settings.
These factors can hinder the growth prospects of the market during the forecast period.
The K-12 online tutoring market is estimated to grow at a CAGR of 12.34{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} between 2022 and 2027. The size of the market is forecasted to increase by USD 97.66 billion. The growing importance of STEM education is notably driving the K-12 online tutoring market growth, although factors such as growing demand for the threat from open tutoring resources and private tutors may impede the market growth.
The K-12 testing and assessment market is estimated to grow at a CAGR of 10.21{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} between 2022 and 2027, and the size of the market is forecasted to increase by USD 9,895.67 million. The increasing use of analytics is notably driving market growth, although factors such as credibility issues may impede the market growth.
K-12 online education market in China Scope
Report Coverage
Details
Base year
2021
Forecast period
2022-2026
Growth momentum & CAGR
Accelerate at a CAGR of 15.45{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}
Leading vendors, market positioning of vendors, competitive strategies, and industry risks
Key companies profiled
Ambow Education Holding Ltd., Beijing Huaxia Dadi Distance Learning, China Online Education Group, ChinaEDU Corp., EIC Education, iTutorGroup Ltd., Kaplan Inc., New Oriental Education and Technology, TAL Education Group, and Xueda Education
Market dynamics
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Exhibit 47: Beijing Huaxia Dadi Distance Learning – Overview
Exhibit 48: Beijing Huaxia Dadi Distance Learning – Product and service
Exhibit 49: Beijing Huaxia Dadi Distance Learning – Key offerings
10.5 China Online Education Group
Exhibit 50: China Online Education Group – Overview
Exhibit 51: China Online Education Group – Product and service
Exhibit 52: China Online Education Group – Key offerings
10.6 ChinaEDU Corp.
Exhibit 53: ChinaEDU Corp. – Overview
Exhibit 54: ChinaEDU Corp. – Business segments
Exhibit 55: ChinaEDU Corp. – Key offerings
Exhibit 56: ChinaEDU Corp. – Segment focus
10.7 EIC Education
Exhibit 57: EIC Education – Overview
Exhibit 58: EIC Education – Product and service
Exhibit 59: EIC Education – Key offerings
10.8 iTutorGroup Ltd.
Exhibit 60: iTutorGroup Ltd. – Overview
Exhibit 61: iTutorGroup Ltd. – Product and service
Exhibit 62: iTutorGroup Ltd. – Key offerings
10.9 Kaplan Inc.
Exhibit 63: Kaplan Inc. – Overview
Exhibit 64: Kaplan Inc. – Product and service
Exhibit 65: Kaplan Inc. – Key offerings
10.10 New Oriental Education and Technology
Exhibit 66: New Oriental Education and Technology – Overview
Exhibit 67: New Oriental Education and Technology – Business segments
Exhibit 68: New Oriental Education and Technology – Key News
Exhibit 69: New Oriental Education and Technology – Key offerings
Exhibit 70: New Oriental Education and Technology – Segment focus
10.11 TAL Education Group
Exhibit 71: TAL Education Group – Overview
Exhibit 72: TAL Education Group – Business segments
Exhibit 73: TAL Education Group – Key offerings
Exhibit 74: TAL Education Group – Segment focus
10.12 Xueda Education
Exhibit 75: Xueda Education – Overview
Exhibit 76: Xueda Education – Business segments
Exhibit 77: Xueda Education – Key offerings
Exhibit 78: Xueda Education – Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 79: Currency conversion rates for US$?
11.3 Research Methodology
Exhibit 80: Research Methodology
Exhibit 81: Validation techniques employed for market sizing?
Exhibit 82: Information sources
11.4 List of abbreviations
Exhibit 83: List of abbreviations
About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
The COVID pandemic has disrupted longstanding trends in health spending, utilization, and employment, and created challenges for insurers to accurately predict their costs and set premiums. In the early months of 2020, use of health services dropped sharply, as elective procedures were canceled, and many people delayed or went without care due to concerns of contracting COVID. Utilization has since rebounded, but there are indications that non-COVID care remains below pre-pandemic levels.
In this brief, we examine how insurance markets performed in 2021, the most recent year with annual data. We use financial data reported by insurance companies to the National Association of Insurance Commissioners (NAIC) and compiled by Mark Farrah Associates to look at medical loss ratios and gross margins in the Medicare Advantage, Medicaid managed care, individual (non-group), and fully insured group (employer) health insurance markets through the end of each year. A more detailed description of each market is included in the Appendix.
We find that, by the end of 2021, gross margins per enrollee had returned to pre-pandemic levels in the Medicare Advantage market, while gross margins in the individual and group markets were lower than pre-pandemic levels and Medicaid margins were higher than pre-pandemic levels. Medicare Advantage plans have far higher per person gross margins—more than double those seen in other markets in 2021.
GROSS MARGINS
One way to assess insurer financial performance is to examine per enrollee gross margins, or the amount by which total premium income exceeds total claims costs per enrollee per year. Gross margins are an indicator of financial performance, but positive margins do not necessarily translate into profitability since they do not account for administrative expenses or tax liabilities. While gross margins are not equivalent to profitability in absolute terms, changes in gross margins can be indicative of changes in profitability (assuming administrative costs and tax liability are similar).
Through the end of 2021, gross margins in the Medicare Advantage market averaged $1,730 per enrollee, similar to levels seen in 2018 and 2019 before the pandemic began. In 2021, gross margins for Medicare Advantage plans were substantially higher than those seen in the individual ($745 per enrollee), fully insured group ($689 per enrollee), and Medicaid managed care ($768 per enrollee) markets.
Among fully insured group plans, gross margins were 17{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} lower in 2021 than in 2019. Individual market gross margins were 36{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} lower in 2021 than in 2019. However, individual market plans were arguably priced too high in the years leading up to the pandemic, as discussed more below. Since the rollout of the ACA Marketplaces in 2014, the individual market has seen substantial volatility in margins (Figure 2) and loss ratios.
On average, gross margins in the Medicaid managed care market were higher in 2021 than they were pre-pandemic. Five publicly traded for-profit firms account for half of all Medicaid managed care organization (MCO) enrollment. Earnings reports from 2021 show continued year-over-year growth in enrollment and Medicaid revenues (for the firms that provide Medicaid-specific revenue information), which could be driving increases in overall Medicaid margins. However, states may use a variety of risk mitigation mechanisms to provide financial protection and limits on financial risk for states and plans that may not be accounted for in the data we used in this analysis. In 2021, more than half of MCO states reported implementing COVID-19 related “risk corridors” (where states and health plans agree to share profit or losses), which led to the recoupment of funds from plans across many states. Gross margins reported for 2021 may not reflect recoupments of funds that may occur after the reporting period.
MEDICAL LOSS RATIOS
Another way to assess insurer financial performance is to look at medical loss ratios, or the percent of premium income that insurers pay out in the form of medical claims. Generally, lower medical loss ratios mean that insurers have more income remaining after paying medical costs to use for administrative costs or keep as profits. Each health insurance market has different administrative needs and costs, so lower medical loss ratios in one market do not necessarily mean that market is more profitable than another market. However, in a given market, if administrative costs hold mostly constant from one year to the next, a change in medical loss ratios could imply a change in profitability.
Medical loss ratios are used in state and federal insurance regulation in a variety of ways. In the commercial insurance (individual and group) markets, insurers must issue rebates to individuals and businesses if their loss ratios fail to reach minimum standards set by the ACA. Medicare Advantage insurers are required to report loss ratios at the contract level; they are also required to issue rebates to the federal government if their MLRs fall short of required levels and are subject to additional penalties if they fail to meet loss ratio requirements for multiple consecutive years. For Medicaid MCOs, CMS requires states to develop capitation rates for Medicaid to achieve an MLR of at least 85{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}. There is no federal requirement for Medicaid plans to pay remittances if they fail to meet their MLR threshold, but a majority of states that contract with MCOs do require remittances in at least some cases.
The medical loss ratios shown in this issue brief differ from the definition of MLR in the ACA and CMS Medicaid managed care final rule, which makes some adjustments for quality improvement and taxes, and do not account for reinsurance, risk corridors, or risk adjustment payments. (Notably, the health insurer tax, which has been permanently repealed starting in 2021, was in effect in 2018 and 2020, but not 2019 or 2021). The chart below shows simple medical loss ratios, or the share of premium income that insurers pay out for benefits, without any modifications (Figure 3).
In 2021, loss ratios were similar across all markets. Simple loss ratios were 87{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in the Medicare Advantage market, 88{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in both the individual and fully insured group markets, and 86{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in the Medicaid managed care market. However, because each market has different administrative needs and costs, this does not imply that the markets are similar to each other in profitability.
Rather, we can look at changes in the direction of loss ratios as an indication of changes in profitability in a given market. Relative to 2019, average loss ratios in the Medicaid managed care market remain lower (implying increased profitability), while average loss ratios in the group and Medicare Advantage markets were somewhat higher than pre-pandemic levels.
Individual market loss ratios in 2021 are substantially higher than those seen in the years leading up to the pandemic. As mentioned earlier, 2018 and 2019 were exceptionally lucrative years for the individual market. Many plans fell short of the ACA’s medical loss ratio requirements and were therefore required to issue large rebates to consumers based on their 2018 and 2019 experience.
DISCUSSION
Using annual financial data reported by insurance companies to state regulators, it appears health insurers in the Medicare Advantage market saw similar financial performance in 2021 as they did in the years leading up to the pandemic. Insurers in the Medicaid managed care market, meanwhile, saw somewhat better performance and commercial insurers (particularly in the individual market) saw worse performance than in the years leading up to the pandemic.
Across all markets, 2021 gross margins were by far the highest for Medicare Advantage plans. Medicare Advantage plans have both higher average costs and higher premiums (largely paid by the federal government), because Medicare covers an older, sicker population. So, while Medicare Advantage insurers spend a similar share of their premiums on benefits as other insurers in other markets, the gross margins—which include profits and administrative costs—of Medicare Advantage plans tend to be higher.
Potentially spurred by the prospect of strong financial returns, the Medicare Advantage market has grown substantially in the last decade, with more than 50{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of eligible beneficiaries expected to enroll in a Medicare Advantage plan in 2023. Insurers that fall short of required loss ratio requirements for multiple years face penalties, including the possibility of being terminated. To avoid such a risk, some Medicare Advantage insurers with loss ratios below 85{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} may take this opportunity to offer new or more generous extra benefits, such as over-the-counter allowances, meals following hospital stays, or transportation, in addition to gym memberships, dental, vision and hearing benefits that are offered nearly universally to help retain and attract new enrollees.
Looking ahead to coming years, the pandemic’s effect on insurer financial performance remains uncertain. The direct costs associated with the pandemic remain hard to predict, as treatment costs may rise or fall depending on new variants or increased population immunity. Additionally, the commercialization of COVID-19 vaccines and treatments will lead to higher prices per dose, but total costs will also depend on the number of doses (e.g., uptake of boosters), which is difficult to predict. There are also the indirect effects of the pandemic to consider. Health care utilization has mostly rebounded to pre-pandemic levels, though there are indications utilization remains suppressed for non-COVID care and there could be additional pent-up demand for care that had been missed or delayed. For Medicaid, the unwinding of the continuous enrollment provision on March 31 means states will begin disenrollments that have been paused since the start of the pandemic and could result in millions of individuals losing Medicaid coverage. Medicaid MCOs may see the overall acuity of their membership increase, which could have implications for overall utilization and costs looking ahead.
This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.
Methods
We analyzed insurer-reported financial data from Health Coverage Portal TM, a market database maintained by Mark Farrah Associates, which includes information from the National Association of Insurance Commissioners (NAIC). We used the “Exhibit of Premiums, Enrollment, and Utilization” report for this analysis. The dataset analyzed in this report does not include California HMOs regulated by California’s Department of Managed Health Care. Additionally, for Medicaid, there are four states (Arizona, California, New York, and Oregon) that have different reporting practices and therefore consistently only have partial NAIC data available.
We excluded plans that were not present in the NAIC demographics file, filed negative values in any of the segments of interest, negative or zero dollars in premiums and claims, or did not report for all variables that were being analyzed. We also excluded plans reporting over 1,000 hospital days per 1,000 member months. We only included plans that were categorized as having a “medical” focus in our analysis and exclude “specialty” plans which are categorized as “ancillary or supplemental benefit plans.” We also excluded any plans from the U.S. territories. We corrected for plans that did not file “member months” or filed a negative or zero “member month” value in the annual statement but did file current year membership by imputing these values. If, after imputing, plans still did not have “member months,” they were excluded.
The group market in this analysis only includes fully insured plans. NAIC defines “Medicaid” as “business where the reporting entity charges a premium and agrees to cover the full medical costs of Medicaid subscribers.” This explicitly excludes Administrative Services Only (ASO) plans. We only use “medical” focused plans to help exclude any specialty plans; however, prepaid ambulatory health plans (PAHPs), prepaid inpatient health plans (PIHPs), or Programs of All-Inclusive Care for the Elderly (PACE) plans may be included in the analysis due to NAIC’s definition of Medicaid.
Gross margins per enrollee were calculated by subtracting the sum of total incurred claims from the sum of unadjusted health premiums earned and dividing by the total number of members.
Premiums for Medicare Advantage plans primarily consist of federal payments made to plans and any additional amounts plans may choose to charge their enrollees. Premiums for Medicare Advantage plans do not include payments for Medicare Part D benefits. Premiums for Medicaid do not reflect contractual adjustments related to risk corridors or other risk-sharing adjustments.
To calculate medical loss ratios, we divided the market-wide sum of total incurred claims by the sum of all unadjusted health premiums earned. Medical loss ratios in this analysis are simple loss ratios and do not adjust for quality improvement expenses, taxes, or risk program payments. For example, the 2016 CMS managed care final rule (CMS-2390-F) allows managed care plans to adjust their medical loss ratio calculations to account for quality improvement expenditures and the removal of estimated Medicaid taxes, licensing, and regulatory fee from the revenues when submitting data to CMS. It should be noted that other organizations and agencies use claims and premiums reported in the “Statement of Revenues & Expenses” for their medical loss ratio calculations.
Appendix
Individual Market. The individual market, which accounted for about 17 million people in the first quarter of 2022, includes coverage purchased by individuals and families through the Affordable Care Act’s exchanges (Marketplaces) as well as coverage purchased directly off-exchange, which includes both plans complying with the ACA’s rules and non-compliant coverage. (e.g., grandfathered policies purchased before the ACA went into effect and some short-term plans). The federal government provides subsidies for low-income people in the Marketplace and includes measures, such as risk adjustment, to help limit the financial liability of insurers. Insurers in the individual market receive premium payments from enrollees, plus any federal subsidies for people in the Marketplaces.
Some plans submitting data on the Exhibit of Premiums Enrollment and Utilization appear to be including some Children’s Health Insurance Program (CHIP) data in their Individual market filings. In a previous version of this analysis, we used the Supplemental Health Care Exhibit to address this. However, in this analysis, we opted to use the EPEU to ensure comparability.
Group Market. The fully insured group market serves employers, their employees and dependents who are enrolled in fully insured health plans. This market includes both small and large group plans, but excludes employer-sponsored insurance plans that are self-funded, which account for 65{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of workers with employer-sponsored insurance. Roughly 30 million people were enrolled in fully insured group market plans in 2021. Plans typically receive premium payments from both employers and their employees.
Medicaid Managed Care. The Medicaid Managed Care market includes managed care organizations (MCOs) that contract with state Medicaid programs to deliver comprehensive acute care (i.e., most physician and hospital services) to enrollees. As of July 2020, more than two-thirds (around 57 million people) of all Medicaid beneficiaries nationally receive most or all of their care from comprehensive risk-based MCOs. There is significant variation across states with respect to services that are covered by MCOs.
In this analysis, the NAIC data we use defines “Medicaid” as “business where the reporting entity charges a premium and agrees to cover the full medical costs of Medicaid subscribers” and only explicitly excludes Administrative Services Only (ASO) plans from their reporting. While we only use “medically” focused plans to help exclude any specialty plans, PAHPs, PIHPs and PACE plans may not be excluded due to NAIC’s definition of Medicaid. Additionally, for Medicaid, there are four states (Arizona, California, New York, and Oregon) that have different reporting practices and therefore consistently only have partial NAIC data available. In other work, KFF defines comprehensive MCOs as managed care plans that provide comprehensive Medicaid acute care services and, in some cases, long-term services and supports as well. This excludes “limited benefit plans” including prepaid ambulatory health plans (PAHPs) and prepaid inpatient health plans (PIHPs) as well as Programs of All-Inclusive Care for the Elderly (PACE) that may be included in this analysis.
Mark Farrah Associates Health Coverage PortalTM includes data from fully capitated risk-based MCOs as well as non-comprehensive Primary Care Case Management (PCCM) plans and some specialty plans. PCCM plans have lower capitated payments than comprehensive MCO agreements because a primary care physician is paid a smaller flat fee for case management and care coordination responsibilities, but the remainder of services an enrollee receives are delivered on a Fee-For-Service agreement.
Medicare Advantage. The Medicare Advantage market provides Medicare-covered benefits through private plans to more than 26 million Medicare beneficiaries in 2021, with enrollment projected to increase to nearly half of all Medicare beneficiaries in 2023. The federal government makes risk-adjusted payments (higher payments for sicker enrollees and lower payments for healthier enrollees) to plans (averaging nearly $12,600 per enrollee in 2021) to cover the cost of benefits covered under Medicare Parts A and B and supplemental benefits, such as dental, vision, hearing, and others, with additional payments for costs associated with prescription drug coverage. Some plans charge enrollees an additional premium.
